-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer
-
2024-515273-10-00
7
2021-10-19
Relapsed or refractory Multiple Myeloma (r/r MM)
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-514494-21-00
4
2020-05-13
autoimmune encephalitis
-
2023-504653-12-00
4
2020-02-10
Patients with previously untreated Richter Transformation or patients
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2022-503001-38-01
5
2025-07-08
HR-positive HER-2- negative Breast Cancer